Showing 2721-2730 of 5646 results for "".
- RightEye: New Research Demonstrates Reliability of Eye Tracking Data to Identify and Measure Severity of Traumatic Brain Injurieshttps://modernod.com/news/righteye-new-research-demonstrates-reliability-of-eye-tracking-data-to-identify-and-measure-severity-of-traumatic-brain-injuries/2476832/RightEye announced the results of a recent study published in the peer-reviewed journal Concussion that shows how RightEye’s FDA-cleared technology accurately measures deficits in certain eye movements that r
- New World Medical Launches Ahmed ClearPath Glaucoma Drainage Devicehttps://modernod.com/news/new-world-medical-launches-ahmed-clearpath-glaucoma-drainage-device/2476814/New World Medical announced the launch of the Ahmed ClearPath glaucoma drainage device, which is available in two sizes, 350 mm2 and 250 mm.2 A unique feature of the Ahmed ClearPath implant is a flexible plate with a contour that closely conforms to the curvature of the eye
- MIGS Devices Continue to Expand Use of Glaucoma Surgeryhttps://modernod.com/news/migs-devices-continue-to-expand-use-of-glaucoma-surgery/2476811/Minimally invasive glaucoma surgery (MIGS) stents account for nearly half of all glaucoma surgical device revenue in 2019, according to a Market Scope report. Market penetration of these stents over the past 5 years has been impressive, but the voluntary recall of the Alcon CyPass in 2018
- Retina Specialist Brett Foxman, MD, Earns U.S. Patent for Scleral Depressorhttps://modernod.com/news/retina-specialist-brett-foxman-md-earns-u-s-patent-for-scleral-depressor/2476788/Brett Foxman, MD, Clinical Service Chief in Ophthalmology at Shore Medical Center in Somers Point, New Jersey, recently won a U.S. patent for his new version of the scleral depressor. Dr. Foxman said after performing thousands of eye surgeries using a tool that had stayed essentially uncha
- Clearside Biomedical Announces Multiple Presentations Delivered at the ASRS Annual Meetinghttps://modernod.com/news/clearside-biomedical-announces-multiple-presentations-delivered-at-the-asrs-annual-meeting/2479557/Clearside Biomedical announced that multiple oral presentations were delivered on Clearside’s pipeline and proprietary SCS Microinjector targeting the suprachoroidal space (SCS) at the American Society of Retinal Specialists (ASRS) Annual Meeting. “Clearside had a widespread presence at t
- EssilorLuxottica, Maker of Ray-Ban Sunglasses, Agrees to Buy GrandVision in $8 Billion Dealhttps://modernod.com/news/ray-ban-maker-agrees-to-buy-grandvision-for-8-billion/2479558/A blockbuster deal in the eyecare retail space was announced on Wednesday as EssilorLuxottica, the maker of Ray-Ban sunglasses, agreed to buy Dutch retailer GrandVision NV in multi-billion dollar deal. Paris-based EssilorLuxottica agreed to buy control (77%) of European rival GrandVision f
- Altris AI Algorithm for Detection of Retinal Conditions on OCT Scans Receives European CE Mark Approvalhttps://modernod.com/news/altris-ai-algorithm-for-detection-of-retinal-conditions-on-oct-scans-receives-european-ce-mark-approval/2479561/Altris AI announced that it has received the CE Mark approval for its Standard Functionality for retinal conditions detection on Optical Coherence Tomography (OCT) scans. Altris AI Standard Functionality is ready for preliminary screening of retinal diseases in clinical practice. Altris AI detect
- Kodiak Sciences Announces Positive Interim Data from Phase 1b Study of KSI-301, a Novel Anti-VEGF Antibody Biopolymer Conjugate for Treatment of Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-announces-positive-interim-data-from-phase-1b-study-of-ksi-301-a-novel-anti-vegf-antibody-biopolymer-conjugate-for-treatment-of-retinal-diseases/2476775/Kodiak Sciences announced positive interim results from the ongoing phase 1b study of KSI-301, its investigational intravitreal anti-VEGF antibody biopolymer conjugate in patients with anti-VEGF treatment-naïve wet age-related macular degeneration (AMD), diabetic mac
- Novartis, Mundipharma Ink Partnership to Enhance Access to Three Asian Countries to Established Medicine Brands for Glaucoma and External Eye Diseaseshttps://modernod.com/news/novartis-mundipharma-ink-partnership-to-enhance-access-to-three-asian-countries-to-established-medicine-brands-for-glaucoma-and-external-eye-diseases/2476771/Novartis and Mundipharma have signed a landmark agreement for the marketing, sales and distribution rights of Novartis medicines in the general ophthalmology disease area in Taiwan of Novartis. This includes medicines for glaucoma and external eye diseases. This f
- Ocular Therapeutix Announces Early Assignment of Permanent and Specific J-Code for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-early-assignment-of-permanent-and-specific-j-code-for-dextenza/2476773/Ocular Therapeutix announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dextenza (dexamethasone ophthalmic insert) 0.4 mg, which is approved for the